The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Acquired resistance to MET inhibition in MET driven NSCLC.
 
Richard Riedel
Consulting or Advisory Role - Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - Lilly; Loxo
 
Carina Heydt
Honoraria - AstraZeneca; Illumina
 
Andreas H. Scheel
Honoraria - Bristol-Myers Squibb; Dako/Agilent Technologies; MSD; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Dako/Agilent Technologies; MSD; Roche
 
Hannah Lea Tumbrink
No Relationships to Disclose
 
Johannes Brägelmann
No Relationships to Disclose
 
Roberta Castiglione
No Relationships to Disclose
 
Lucia Nogova
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Celgene; Novartis; Pfizer
 
Diana S.Y. Abdulla
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Healthcare Consulting Cologne; MSD; Novartis; Roche Pharma AG
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Healthcare Consulting Cologne; MSD; Novartis; Roche Pharma AG
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Janssen Research & Development (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Loxo; Merck; Novartis; Roche Pharma AG
 
Sebastian Yves Friedrich Michels
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer; Roche Pharma AG
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Matthias Scheffler
Honoraria - Boehringer Ingelheim; Healthcare Consulting Cologne; Mediolanum Farmaceutici; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Mediolanum Farmaceutici; Roche; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim; Mediolanum Farmaceutici
 
Rieke Nila Fischer
Honoraria - Bristol-Myers Squibb; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Mediolanum Farmaceutici
 
Sophia Koleczko
No Relationships to Disclose
 
Sabine Merkelbach-Bruse
Honoraria - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
 
Martin Sos
Research Funding - Novartis; Novartis
 
Reinhard Büttner
Employment - Targovax
Leadership - Targovax
Stock and Other Ownership Interests - Targovax
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Expert Testimony - MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Juergen Wolf
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ignyta; Janssen; Lilly; Loxo/Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer